Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab in APECED Enteritis
NCT07202598Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2025
- Primary completion
- Mar 2031
- Countries
- 1
01
Overview
A Phase 2 trial of emapalumab in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), sponsored by National Institute of Allergy and Infectious Diseases. Started Nov 2025; status: recruiting.
02
Drugs
emapalumab
03
Conditions
autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
Beyond the preview
Go deeper on NCT07202598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07202598.